CytomX Therapeutics, Inc. (CTMX) — Analyst outlook / Analyst consensus target is. Based on 21 analyst ratings, the consensus is bullish — 17 Buy, 4 Hold.
The consensus price target is $11.60 (low: $10.00, high: $16.00), representing an upside of 155.5% from the current price $4.54.
Analysts estimate Earnings Per Share (EPS) of $-0.04 and revenue of $0.12B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $0.38 vs est $-0.04 (beat +978.2%). 2025: actual $-0.15 vs est $-0.03 (missed -436.3%). Analyst accuracy: 4%.
CTMX Stock — 12-Month Price Forecast
$11.60
▲ +155.51% Upside
Average Price Target
Based on 21 Wall Street analysts offering 12-month price targets for CytomX Therapeutics, Inc., the average price target is $11.60, with a high forecast of $16.00, and a low forecast of $10.00.
The average price target represents a +155.51% change from the last price of $4.54.
Highest Price Target
$16.00
Average Price Target
$11.60
Lowest Price Target
$10.00
CTMX Analyst Ratings
Buy
Based on 21 analysts giving stock ratings to CytomX Therapeutics, Inc. in the past 3 months
EPS Estimates — CTMX
4%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual $0.38
vs Est –$0.04
▲ 111.4% off
2025
Actual –$0.15
vs Est –$0.03
▼ 81.4% off
Profitability Outlook
Company has mixed profitability — some years profitable, some at a loss. Analysts expect losses to continue near-term.
Revenue Estimates — CTMX
87%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.138B
vs Est $0.116B
▲ 16.3% off
2025
Actual $0.076B
vs Est $0.083B
▼ 8.8% off
Revenue Trend
Revenue has declined over the period shown. Analysts forecast significant revenue growth ahead.
